With the exclusion of cancer patients in all high-impact heart failure intervention randomised controlled trials regarding the efficacy of, for example, ACE inhibitors and beta-blockers, the response rate of patients with CTRCD to conventional heart failure therapy has not been thoroughly investigated and evidence-based decision-making on optimal treatment is lacking [48]. The gene discussed is ACE; the disease is heart failure.